The emerging importance of Non-HLA autoantibodies in kidney transplant complications

Journal of the American Society of Nephrology

Volumn 28, Issue 2, 2017, Pages 400-406

  Cardinal, Héloise ^a,b   Dieudé, Mélanie ^a,b   Hébert, Marie Josée ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Canadian National Transplant Research Program   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HLA ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIBODY PRODUCTION; BLOOD VESSEL INJURY; CHRONIC GRAFT REJECTION; DISEASE EXACERBATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TISSUE INJURY; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; COMPLICATION; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ANIMALS; AUTOANTIBODIES; CHRONIC DISEASE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION IMMUNOLOGY;

EID: 85020290065     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016070756     Document Type: Review

References (52)

1. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: 235-242, 1996
2. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730, 1999
3. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, Stewart DE, Cherikh WS, Wainright JL, Snyder JJ, Israni AK, Kasiske BL: OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant 14 [Suppl 1]: 11-44, 2014
4. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X: Antibodymediated vascular rejection of kidney allografts: A population-based study. Lancet 381: 313-319, 2013
5. Witt CA, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR: Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 32: 1034-1040, 2013
6. Khan MA, Nicolls MR: Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol 735: 233-246, 2013
7. Dragun D, Catar R, Philippe A: Non-HLA antibodies in solid organ transplantation: Recent concepts and clinical relevance. Curr Opin Organ Transplant 18: 430-435, 2013
8. Amico P, Hönger G, Bielmann D, Lutz D, GarzoniD, Steiger J, Mihatsch MJ, Dragun D, Schaub S: Incidence and prediction of early antibody-mediated rejection due to nonhuman leukocyte antigen-antibodies. Transplantation 85: 1557-1563, 2008
9. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G: Detection of donorspecific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 76: 395-400, 2003
10. Zhang M, Carroll MC: Natural IgM-mediated innate autoimmunity: A new target for early intervention of ischemia-reperfusion injury. Expert Opin Biol Ther 7: 1575-1582, 2007
11. Subramanian V, Ramachandran S, Banan B, Bharat A, Wang X, Benshoff N, Kreisel D, Gelman AE, Mohanakumar T: Immune response to tissue-restricted self-antigens induces airway inflammation and fibrosis following murine lung transplantation. Am J Transplant 14: 2359-2366, 2014
12. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558-569, 2005
13. Gao B, Moore C, Porcheray F, Rong C, Abidoglu C, DeVito J, Paine R, Girouard TC, Saidman SL, Schoenfeld D, Levin B, Wong W, Elias N, Schuetz C, Rosales I, Fu Y, Zorn E: Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant 14: 1581-1591, 2014
14. Klassen J, Milgrom FM, McCluskey RT: Studies of the antigens involved in an immunologic renal tubular lesion in rabbits. Am J Pathol 88: 135-144, 1977
15. Porcheray F, Fraser JW, Gao B, McColl A, DeVito J, Dargon I, Helou Y, Wong W, Girouard TC, Saidman SL, Colvin RB, Palmisano A, Maggiore U, Vaglio A, Smith RN, Zorn E: Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. Am J Transplant 13: 2590-2600, 2013
16. Joosten SA, Sijpkens YW, van Ham V, Trouw LA, van der Vlag J, van den Heuvel B, van Kooten C, Paul LC: Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5: 383-393, 2005
17. Rose ML: Role of anti-vimentin antibodies in allograft rejection. Hum Immunol 74: 1459-1462, 2013
18. Carter V, Shenton BK, Jaques B, Turner D, Talbot D, Gupta A, Chapman CE, Matthews CJ, Cavanagh G: Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 37: 654-657, 2005
19. Carter V, Howell WM: Vimentin antibody production in transplant patients and immunomodulatory effects of vimentin in-vitro. Hum Immunol 74: 1463-1469, 2013
20. Raymond MA, Désormeaux A, Laplante P, Vigneault N, Filep JG, Landry K, Pshezhetsky AV, Hébert MJ: Apoptosis of endothelial cells triggers a caspase-dependent antiapoptotic paracrine loop active on VSMC. FASEB J 18: 705-707, 2004
21. Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y, Bernard M, Raymond Y, Hébert MJ: Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J Immunol 174: 5740-5749, 2005
22. Ishii Y, Sawada T, Kubota K, Fuchinoue S, Teraoka S, Shimizu A: Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 67: 321-332, 2005
23. Soulez M, Pilon EA, Dieudé M, Cardinal H, Brassard N, Qi S, Wu SJ, Durocher Y, Madore F, Perreault C, Hébert MJ: The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res 110: 94-104, 2012
24. Cardinal H, Dieudé M, Brassard N, Qi S, Patey N, Soulez M, Beillevaire D, Echeverry F, Daniel C, Durocher Y, Madore F, Hébert MJ: Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 13: 861-874, 2013
25. Angaswamy N, Klein C, Tiriveedhi V, Gaut J, Anwar S, Rossi A, Phelan D, Wellen JR, Shenoy S, Chapman WC, Mohanakumar T: Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy. Am J Transplant 14: 685-693, 2014
26. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, Yacoub MH, Rose ML: Antivimentin antibodies are an independent predictor of transplantassociated coronary artery disease after cardiac transplantation. Transplantation 71: 886-892, 2001
27. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML: Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 170: 1415-1427, 2007
28. Bharat A, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T: Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 90: 1094-1101, 2010
29. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kühl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, Gollasch M, KueblerWM, Bock S, BurmesterGR, Dragun D, Riemekasten G: Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190: 808-817, 2014
30. Kill A, Tabeling C, Undeutsch R, Kühl AA, Günther J, RadicM, BeckerMO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, Riemekasten G: Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16: R29, 2014
31. Xiong J, Liang Y, Yang H, Zhu F, Wang Y: The role of angiotensin II type 1 receptoractivating antibodies in patients with lupus nephritis. Int J Clin Pract 67: 1066-1067, 2013
32. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC III , Xia Y, Kellems RE: Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 110: 1612-1619, 2004
33. Hönger G, Cardinal H, Dieudé M, Buser A, Hösli I, Dragun D, Hébert MJ, Schaub S: Human pregnancy and generation of antiangiotensin receptor and anti-perlecan antibodies. Transpl Int 27: 467-474, 2014
34. Zhang M, Alicot EM, Carroll MC: Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol Immunol 45: 4036-4039, 2008
35. Zhang M, Alicot EM, Chiu I, Li J, Verna N, Vorup-Jensen T, Kessler B, Shimaoka M, Chan R, FriendD, Mahmood U, Weissleder R, Moore FD, Carroll MC: Identification of the target self-antigens in reperfusion injury. J Exp Med 203: 141-152, 2006
36. Zhang M, Austen WG Jr. , Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr. , Carroll MC: Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 101: 3886-3891, 2004
37. Chan RK, VernaN, Afnan J, Zhang M, Ibrahim S, Carroll MC, Moore FD Jr. : Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. Surgery 139: 236-243, 2006
38. HaasMS, Alicot EM, Schuerpf F, Chiu I, Li J, Moore FD, Carroll MC: Blockade of selfreactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res 87: 618-627, 2010
39. Yang B, Dieudé M, Hamelin K, Hénault-Rondeau M, Patey N, Turgeon J, Lan S, Pomerleau L, Quesnel M, Peng J, Tremblay J, Shi Y, Chan JS, Hébert MJ, Cardinal H: Anti-lG3 antibodies aggravate renal ischemia reperfusion injury and long-term renal allograft dysfunction [published online ahead of print May 12, 2016]. Am J Transplant doi: 10.1111/ajt.13866
40. HaaseM, Bellomo R, Albert C, Vanpoucke G, Thomas G, Laroy W, Verleysen K, Kropf S, Kuppe H, Hetzer R, Haase-Fielitz A: The identification of three novel biomarkers of major adverse kidney events. Biomarkers Med 8: 1207-1217, 2014
41. Lukitsch I, Kehr J, Chaykovska L, Wallukat G, Nieminen-Kelhä M, Batuman V, Dragun D, Gollasch M: Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 94: 8-13, 2012
42. Tarlinton DM, McLean M, Nossal GJ: B1 and B2 cells differ in their potential to switch immunoglobulin isotype. Eur J Immunol 25: 3388-3393, 1995
43. Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG: Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8: E60726, 2013
44. Avrameas S, Selmi C: Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun 41: 46-49, 2013
45. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, Binder CJ: Oxidationspecific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119: 1335-1349, 2009
46. Pilon EA, Dieudé M, Qi S, Hamelin K, Pomerleau L, Beillevaire D, Durocher Y, Zutter M, Coutu D, Perreault C, Hébert MJ: The perlecan fragment LG3 regulates homing of mesenchymal stem cells and neointima formation during vascular rejection. Am J Transplant 15: 1205-1218, 2015
47. Dieudé M, Bell C, Turgeon J, Beillevaire D, Pomerleau L, Yang B, Hamelin K, Qi S, Pallet N, Béland C, Dhahri W, Cailhier JF, Rousseau M, Duchez AC, Lévesque T, Lau A, Rondeau C, Gingras D, Muruve D, Rivard A, Cardinal H, Perreault C, Desjardins M, Boilard É, Thibault P, Hébert MJ: The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med 7: 318ra200, 2015
48. Li L, Wadia P, Chen R, Kambham N, Naesens M, Sigdel TK, Miklos DB, Sarwal MM, Butte AJ: Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci U S A 106: 4148-4153, 2009
49. Basile DP, Donohoe D, Roethe K, Osborn JL: Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. AmJ Physiol Renal Physiol 281: F887-F899, 2001
50. Basile DP, Friedrich JL, Spahic J, Knipe N, Mang H, Leonard EC, Changizi-Ashtiyani S, Bacallao RL, Molitoris BA, Sutton TA: Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol 300: F721-F733, 2011
51. Molitoris BA: Therapeutic translation in acute kidney injury: The epithelial/endothelial axis. J Clin Invest 124: 2355-2363, 2014
52. Jobert A, Rao N, Deayton S, Bennett GD, Brealey J, Nolan J, Carroll RP, Dragun D, Coates PT: Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation. Nephrology (Carlton) 20[Suppl 1]: 10-12, 2015